The Experts below are selected from a list of 951 Experts worldwide ranked by ideXlab platform
Bruce R Russell - One of the best experts on this subject based on the ideXlab platform.
-
acute effects of bzp tfmpp and the combination of bzp and tfmpp in comparison to dexamphetamine on an auditory oddball task using electroencephalography a single dose study
Psychopharmacology, 2016Co-Authors: Grace Y. Wang, Louise E Curley, Ian J Kirk, John J. Sollers, Robert R Kydd, Bruce R RussellAbstract:Rationale Piperazine-based designer drugs such as Benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) have been marketed and sold as legal alternatives to dexamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) until 2008 in New Zealand. When administered in combination, BZP + TFMPP have been reported to produce drug-drug synergism in rodents by stimulating the release of dopamine and serotonin.
-
Acute effects of the designer drugs Benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) using functional magnetic resonance imaging (fMRI) and the Stroop task--a pilot study.
Psychopharmacology, 2015Co-Authors: Louise E Curley, Ian J Kirk, Robert R Kydd, Michelle C. Robertson, Avinesh Pillai, Nicolas A. Mcnair, Heeseung Lee, Bruce R RussellAbstract:Rationale A novel group of designer drugs containing Benzylpiperazine (BZP) and/or trifluoromethylphenylpiperazine (TFMPP) have been available worldwide for more than a decade; however, their effects on human brain function have not been extensively described.
-
Determining the subjective and physiological effects of BZP combined with TFMPP in human males.
Psychopharmacology, 2010Co-Authors: Maree-ann Jensen, Robert R Kydd, Bruce R RussellAbstract:Rationale ‘Party Pills’ containing Benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) have been used in a recreational context since the 1990s and, prior to April 2008, were legally available in New Zealand. Taken together, they have been reported to produce a ‘high’ similar to that produced by 3,4-methylenedioxymethamphetamine (MDMA).
-
Effects of trifluoromethylphenylpiperazine (TFMPP) on interhemispheric communication
Psychopharmacology, 2010Co-Authors: Robert R Kydd, Ian J Kirk, Bruce R RussellAbstract:Background ‘Party Pills’ containing trifluoromethylphenylpiperazine (TFMPP) and Benzylpiperazine are legally available in many countries and marketed as safe alternatives to other illicit substances such as methamphetamine and methylenedioxymethamphetamine (or Ecstasy). They have gained huge popularity around the world, especially amongst young adults. However, there is no information currently available describing the acute neurophysiological effects of these psychoactive drugs in humans. The purpose of this study is to investigate the effects of TFMPP on central information processing speed in humans.
-
Validation of an LC–MS Method for the Detection and Quantification of BZP and TFMPP and their Hydroxylated Metabolites in Human Plasma and its Application to the Pharmacokinetic Study of TFMPP in Humans*
Journal of Forensic Sciences, 2010Co-Authors: Ushtana Antia, Malcolm Tingle, Bruce R RussellAbstract:An LC-MS method was developed for Benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP), constituents of ''party pills'' or ''legal herbal highs,'' and their metabolites in human blood plasma. Compounds were resolved using a mixture of ammonium formate (pH 4.5, 0.01 M) and acetonitrile (flow rate of 1.0 mL ⁄ min) with a C18 column. Calibration curves were linear from 1 to 50 ng ⁄ mL (R 2 > 0.99); the lower limit of quantification (LLOQ) was 5 ng ⁄ mL; the accuracy was >90%; the intra- and interday relative standard deviations (R.S.D) were
Bruce E. Blough - One of the best experts on this subject based on the ideXlab platform.
-
selective suppression of cocaine versus food maintained responding by monoamine releasers in rhesus monkeys Benzylpiperazine phenmetrazine and 4 benzylpiperidine
Journal of Pharmacology and Experimental Therapeutics, 2009Co-Authors: S. Stevens Negus, Michael H. Baumann, Richard B. Rothman, Nancy K. Mello, Bruce E. BloughAbstract:Monoamine releasers constitute one class of drugs currently under investigation as potential agonist medications for the treatment of cocaine dependence. The efficacy and safety of monoamine releasers as candidate medications may be influenced in part by their relative potency to release dopamine and serotonin, and we reported previously that releasers with approximately 30-fold selectivity for dopamine versus serotonin release may be especially promising. The present study examined the effects of the releasers Benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine, which have 20- to 48-fold selectivity in vitro for releasing dopamine versus serotonin. In an assay of cocaine discrimination, rhesus monkeys were trained to discriminate 0.4 mg/kg i.m. cocaine from saline in a two-key, food-reinforced procedure. Each of the releasers produced a dose- and time-dependent substitution for cocaine. 4-Benzylpiperidine had the most rapid onset and shortest duration of action. Phenmetrazine and Benzylpiperazine had slower onsets and longer durations of action. In an assay of cocaine self-administration, rhesus monkeys were trained to respond for cocaine injections and food pellets under a second order schedule. Treatment for 7 days with each of the releasers produced a dose-dependent and selective reduction in self-administration of cocaine (0.01 mg/kg/injection). The most selective effects were produced by phenmetrazine. Phenmetrazine also produced a downward shift in the cocaine self-administration dose effect curve, virtually eliminating responding maintained by a 30-fold range of cocaine doses (0.0032–0.1 mg/kg/injection) while having only small and transient effects on food-maintained responding. These findings support the potential utility of dopamine-selective releasers as candidate treatments for cocaine dependence.
-
Selective Suppression of Cocaine- versus Food-Maintained Responding by Monoamine Releasers in Rhesus Monkeys: Benzylpiperazine, (+)Phenmetrazine, and 4-Benzylpiperidine
The Journal of pharmacology and experimental therapeutics, 2009Co-Authors: S. Stevens Negus, Michael H. Baumann, Richard B. Rothman, Nancy K. Mello, Bruce E. BloughAbstract:Monoamine releasers constitute one class of drugs currently under investigation as potential agonist medications for the treatment of cocaine dependence. The efficacy and safety of monoamine releasers as candidate medications may be influenced in part by their relative potency to release dopamine and serotonin, and we reported previously that releasers with approximately 30-fold selectivity for dopamine versus serotonin release may be especially promising. The present study examined the effects of the releasers Benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine, which have 20- to 48-fold selectivity in vitro for releasing dopamine versus serotonin. In an assay of cocaine discrimination, rhesus monkeys were trained to discriminate 0.4 mg/kg i.m. cocaine from saline in a two-key, food-reinforced procedure. Each of the releasers produced a dose- and time-dependent substitution for cocaine. 4-Benzylpiperidine had the most rapid onset and shortest duration of action. Phenmetrazine and Benzylpiperazine had slower onsets and longer durations of action. In an assay of cocaine self-administration, rhesus monkeys were trained to respond for cocaine injections and food pellets under a second order schedule. Treatment for 7 days with each of the releasers produced a dose-dependent and selective reduction in self-administration of cocaine (0.01 mg/kg/injection). The most selective effects were produced by phenmetrazine. Phenmetrazine also produced a downward shift in the cocaine self-administration dose effect curve, virtually eliminating responding maintained by a 30-fold range of cocaine doses (0.0032–0.1 mg/kg/injection) while having only small and transient effects on food-maintained responding. These findings support the potential utility of dopamine-selective releasers as candidate treatments for cocaine dependence.
S. Stevens Negus - One of the best experts on this subject based on the ideXlab platform.
-
selective suppression of cocaine versus food maintained responding by monoamine releasers in rhesus monkeys Benzylpiperazine phenmetrazine and 4 benzylpiperidine
Journal of Pharmacology and Experimental Therapeutics, 2009Co-Authors: S. Stevens Negus, Michael H. Baumann, Richard B. Rothman, Nancy K. Mello, Bruce E. BloughAbstract:Monoamine releasers constitute one class of drugs currently under investigation as potential agonist medications for the treatment of cocaine dependence. The efficacy and safety of monoamine releasers as candidate medications may be influenced in part by their relative potency to release dopamine and serotonin, and we reported previously that releasers with approximately 30-fold selectivity for dopamine versus serotonin release may be especially promising. The present study examined the effects of the releasers Benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine, which have 20- to 48-fold selectivity in vitro for releasing dopamine versus serotonin. In an assay of cocaine discrimination, rhesus monkeys were trained to discriminate 0.4 mg/kg i.m. cocaine from saline in a two-key, food-reinforced procedure. Each of the releasers produced a dose- and time-dependent substitution for cocaine. 4-Benzylpiperidine had the most rapid onset and shortest duration of action. Phenmetrazine and Benzylpiperazine had slower onsets and longer durations of action. In an assay of cocaine self-administration, rhesus monkeys were trained to respond for cocaine injections and food pellets under a second order schedule. Treatment for 7 days with each of the releasers produced a dose-dependent and selective reduction in self-administration of cocaine (0.01 mg/kg/injection). The most selective effects were produced by phenmetrazine. Phenmetrazine also produced a downward shift in the cocaine self-administration dose effect curve, virtually eliminating responding maintained by a 30-fold range of cocaine doses (0.0032–0.1 mg/kg/injection) while having only small and transient effects on food-maintained responding. These findings support the potential utility of dopamine-selective releasers as candidate treatments for cocaine dependence.
-
Selective Suppression of Cocaine- versus Food-Maintained Responding by Monoamine Releasers in Rhesus Monkeys: Benzylpiperazine, (+)Phenmetrazine, and 4-Benzylpiperidine
The Journal of pharmacology and experimental therapeutics, 2009Co-Authors: S. Stevens Negus, Michael H. Baumann, Richard B. Rothman, Nancy K. Mello, Bruce E. BloughAbstract:Monoamine releasers constitute one class of drugs currently under investigation as potential agonist medications for the treatment of cocaine dependence. The efficacy and safety of monoamine releasers as candidate medications may be influenced in part by their relative potency to release dopamine and serotonin, and we reported previously that releasers with approximately 30-fold selectivity for dopamine versus serotonin release may be especially promising. The present study examined the effects of the releasers Benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine, which have 20- to 48-fold selectivity in vitro for releasing dopamine versus serotonin. In an assay of cocaine discrimination, rhesus monkeys were trained to discriminate 0.4 mg/kg i.m. cocaine from saline in a two-key, food-reinforced procedure. Each of the releasers produced a dose- and time-dependent substitution for cocaine. 4-Benzylpiperidine had the most rapid onset and shortest duration of action. Phenmetrazine and Benzylpiperazine had slower onsets and longer durations of action. In an assay of cocaine self-administration, rhesus monkeys were trained to respond for cocaine injections and food pellets under a second order schedule. Treatment for 7 days with each of the releasers produced a dose-dependent and selective reduction in self-administration of cocaine (0.01 mg/kg/injection). The most selective effects were produced by phenmetrazine. Phenmetrazine also produced a downward shift in the cocaine self-administration dose effect curve, virtually eliminating responding maintained by a 30-fold range of cocaine doses (0.0032–0.1 mg/kg/injection) while having only small and transient effects on food-maintained responding. These findings support the potential utility of dopamine-selective releasers as candidate treatments for cocaine dependence.
Robert R Kydd - One of the best experts on this subject based on the ideXlab platform.
-
acute effects of bzp tfmpp and the combination of bzp and tfmpp in comparison to dexamphetamine on an auditory oddball task using electroencephalography a single dose study
Psychopharmacology, 2016Co-Authors: Grace Y. Wang, Louise E Curley, Ian J Kirk, John J. Sollers, Robert R Kydd, Bruce R RussellAbstract:Rationale Piperazine-based designer drugs such as Benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) have been marketed and sold as legal alternatives to dexamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) until 2008 in New Zealand. When administered in combination, BZP + TFMPP have been reported to produce drug-drug synergism in rodents by stimulating the release of dopamine and serotonin.
-
Acute effects of the designer drugs Benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) using functional magnetic resonance imaging (fMRI) and the Stroop task--a pilot study.
Psychopharmacology, 2015Co-Authors: Louise E Curley, Ian J Kirk, Robert R Kydd, Michelle C. Robertson, Avinesh Pillai, Nicolas A. Mcnair, Heeseung Lee, Bruce R RussellAbstract:Rationale A novel group of designer drugs containing Benzylpiperazine (BZP) and/or trifluoromethylphenylpiperazine (TFMPP) have been available worldwide for more than a decade; however, their effects on human brain function have not been extensively described.
-
Determining the subjective and physiological effects of BZP combined with TFMPP in human males.
Psychopharmacology, 2010Co-Authors: Maree-ann Jensen, Robert R Kydd, Bruce R RussellAbstract:Rationale ‘Party Pills’ containing Benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) have been used in a recreational context since the 1990s and, prior to April 2008, were legally available in New Zealand. Taken together, they have been reported to produce a ‘high’ similar to that produced by 3,4-methylenedioxymethamphetamine (MDMA).
-
Effects of trifluoromethylphenylpiperazine (TFMPP) on interhemispheric communication
Psychopharmacology, 2010Co-Authors: Robert R Kydd, Ian J Kirk, Bruce R RussellAbstract:Background ‘Party Pills’ containing trifluoromethylphenylpiperazine (TFMPP) and Benzylpiperazine are legally available in many countries and marketed as safe alternatives to other illicit substances such as methamphetamine and methylenedioxymethamphetamine (or Ecstasy). They have gained huge popularity around the world, especially amongst young adults. However, there is no information currently available describing the acute neurophysiological effects of these psychoactive drugs in humans. The purpose of this study is to investigate the effects of TFMPP on central information processing speed in humans.
-
Determining the subjective and physiological effects of BZP on human females
Psychopharmacology, 2009Co-Authors: Nisha Bangs, Robert R Kydd, Bruce R RussellAbstract:Background “Party pills” containing Benzylpiperazine (BZP) used to be widely and legally available as recreational drugs in New Zealand. There are only two published trials on human subjects (1973), which suggested that 100 mg of BZP produced subjective and physiological effects similar to 10 mg of dexamphetamine. The purpose of this study is to further investigate the subjective and physiological responses to BZP in females.
Michael H. Baumann - One of the best experts on this subject based on the ideXlab platform.
-
selective suppression of cocaine versus food maintained responding by monoamine releasers in rhesus monkeys Benzylpiperazine phenmetrazine and 4 benzylpiperidine
Journal of Pharmacology and Experimental Therapeutics, 2009Co-Authors: S. Stevens Negus, Michael H. Baumann, Richard B. Rothman, Nancy K. Mello, Bruce E. BloughAbstract:Monoamine releasers constitute one class of drugs currently under investigation as potential agonist medications for the treatment of cocaine dependence. The efficacy and safety of monoamine releasers as candidate medications may be influenced in part by their relative potency to release dopamine and serotonin, and we reported previously that releasers with approximately 30-fold selectivity for dopamine versus serotonin release may be especially promising. The present study examined the effects of the releasers Benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine, which have 20- to 48-fold selectivity in vitro for releasing dopamine versus serotonin. In an assay of cocaine discrimination, rhesus monkeys were trained to discriminate 0.4 mg/kg i.m. cocaine from saline in a two-key, food-reinforced procedure. Each of the releasers produced a dose- and time-dependent substitution for cocaine. 4-Benzylpiperidine had the most rapid onset and shortest duration of action. Phenmetrazine and Benzylpiperazine had slower onsets and longer durations of action. In an assay of cocaine self-administration, rhesus monkeys were trained to respond for cocaine injections and food pellets under a second order schedule. Treatment for 7 days with each of the releasers produced a dose-dependent and selective reduction in self-administration of cocaine (0.01 mg/kg/injection). The most selective effects were produced by phenmetrazine. Phenmetrazine also produced a downward shift in the cocaine self-administration dose effect curve, virtually eliminating responding maintained by a 30-fold range of cocaine doses (0.0032–0.1 mg/kg/injection) while having only small and transient effects on food-maintained responding. These findings support the potential utility of dopamine-selective releasers as candidate treatments for cocaine dependence.
-
Selective Suppression of Cocaine- versus Food-Maintained Responding by Monoamine Releasers in Rhesus Monkeys: Benzylpiperazine, (+)Phenmetrazine, and 4-Benzylpiperidine
The Journal of pharmacology and experimental therapeutics, 2009Co-Authors: S. Stevens Negus, Michael H. Baumann, Richard B. Rothman, Nancy K. Mello, Bruce E. BloughAbstract:Monoamine releasers constitute one class of drugs currently under investigation as potential agonist medications for the treatment of cocaine dependence. The efficacy and safety of monoamine releasers as candidate medications may be influenced in part by their relative potency to release dopamine and serotonin, and we reported previously that releasers with approximately 30-fold selectivity for dopamine versus serotonin release may be especially promising. The present study examined the effects of the releasers Benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine, which have 20- to 48-fold selectivity in vitro for releasing dopamine versus serotonin. In an assay of cocaine discrimination, rhesus monkeys were trained to discriminate 0.4 mg/kg i.m. cocaine from saline in a two-key, food-reinforced procedure. Each of the releasers produced a dose- and time-dependent substitution for cocaine. 4-Benzylpiperidine had the most rapid onset and shortest duration of action. Phenmetrazine and Benzylpiperazine had slower onsets and longer durations of action. In an assay of cocaine self-administration, rhesus monkeys were trained to respond for cocaine injections and food pellets under a second order schedule. Treatment for 7 days with each of the releasers produced a dose-dependent and selective reduction in self-administration of cocaine (0.01 mg/kg/injection). The most selective effects were produced by phenmetrazine. Phenmetrazine also produced a downward shift in the cocaine self-administration dose effect curve, virtually eliminating responding maintained by a 30-fold range of cocaine doses (0.0032–0.1 mg/kg/injection) while having only small and transient effects on food-maintained responding. These findings support the potential utility of dopamine-selective releasers as candidate treatments for cocaine dependence.